What to Watch When Bristol-Myers Squibb Reports End of Year Earnings

Can Bristol-Myers put its capital to good use and push its hepatitis and oncology segments to success?

Jan 22, 2014 at 7:30AM

Bristol-Myer's Squibb (NYSE:BMY) led its big pharma peers in 2013 as its stock climbed an incredible 60%. With that momentum carrying through to some important catalysts in 2014, here are three topics to watch when Bristol-Myers reports earnings on Friday.

Fighting against hepatitis C
Bristol-Myers was a strong contender in the race to cure hepatitis C with its combination therapy of daclatasvir and Gilead's sofosbuvir (now marketed as Sovaldi). But when Gilead chose to forego a partnership with Bristol-Myers and develop its own NS5A inhibitor ledipasvir, Bristol had to move forward alone with daclatasvir's development.

Now Bristol-Myers is looking for a place for daclatasvir, and there are certainly opportunities. Daclatasvir looks to be headed for shelves in Europe, where the European Medicines Agency allows for compassionate use of the daclatasvir-sofosbuvir combo despite Gilead's reluctance to co-market the drugs. In the US, Bristol-Myers is looking to Vertex (NASDAQ:VRTX) and its drug VX-135, which posted a sustained viral response rate of 83% after 4 weeks of treatment in a Phase 2a trial. Look for management to discuss these results in the context of the broader competitive market, which is already crowded with some big names.

The promise of nivolumab
Cancer immunotherapy, especially PD-1 inhibitor nivolumab, has been the talk of the town since the American Society of Clinical Oncology meeting in June. Bristol-Myers unveiled impressive data at the conference, demonstrating a 53% response rate when given with Yervoy to patients with advanced melanoma in a Phase 1 trial. Several Phase 3 trials of nivolumab with and without Yervoy are also under way.

The promise of PD-1 inhibitors is their ability to coax the immune system into killing tumor cells, avoiding some of the debilitating side effects of classical chemotherapy. That promise has drawn the likes of Merck (NYSE:MRK), Roche, and others into the field.

It seemed for most of the year that nivolumab had the upper hand, but recently Merck began a rolling submission for FDA approval of MK-3475 for treatment of melanoma in patients already taking Yervoy. Now Bristol-Myers' investors are left waiting for nivolumab to make its move. You can bet that will be the largest source of questions on the conference call, as nivolumab represents a major point of excitement in any investment thesis.

Capital allocation
Like most of its peers, Bristol-Myers has been navigating the loss of a major revenue stream. Now more than a year since loss of Plavix's patent protection, Bristol-Myers' revenue growth will provide a more clear picture of the growth of its current assets.

Those cash flows will be supplemented by $2.7 billion after Bristol-Myers sold its stake in a diabetes collaboration with AstraZenica. The deal is an important step in Bristol's reorganization. It not only helps the company streamline its business and escape a competitive diabetes market, it also provides plenty of capital to focus on core areas of strength.

It would not be surprising to see Bristol-Myers continue to invest in its immuno-oncology segment, especially given the promise of Yervoy and nivolumab. It seems most likely that Bristol will use the cash to pick up some developmental assets to pair with the two, as the race against Merck will largely come down to the adoption of PD-1 inhibitors as an adjunct to targeted therapies.

Bristol-Myers Squibb Isn't the Only Dividend Stock To Watch
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Seth Robey has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers